Impact of multisite colonization and comparative microbiological outcomes of colistin-sulbactam vs. colistin-tigecycline in CRAB hospital-acquired pneumonia: a propensity score-matched analysis
Abstract
Background The optimal combination therapy for carbapenem-resistant Acinetobacter baumannii (CRAB) pneumonia remains controversial. This study aimed to compare the microbiological efficacy, clinical outcomes, and safety of colistin-sulbactam versus colistin-tigecycline regimens in patients with CRAB hospital-acquired or ventilator-associated pneumonia (HAP/VAP). Methods A single-center, retrospective cohort study was conducted from 2019 to 2024. Adult patients with culture-confirmed CRAB HAP/VAP receiving either colistin-sulbactam (Group A) or colistin-tigecycline (Group B) for ≥72 hours were included. Propensity score matching (PSM) was utilized to balance baseline covariates, including APACHE II scores and renal function. The primary endpoint was microbiological eradication at Day 7; secondary endpoints included 28-day all-cause mortality, clinical cure, and adverse events. Results Among 176 eligible patients, 42 matched pairs (n=84) were generated. The colistin-sulbactam group achieved significantly higher microbiological eradication rates at Day 7 compared to the colistin-tigecycline group (66.7% vs. 40.5%; P = 0.013). Subgroup analysis revealed that this benefit was particularly pronounced in patients with extensively drug-resistant (XDR) strains (OR 4.75; 95% CI 1.58–14.26) and those with multisite colonization. Clinical cure rates were also higher in Group A (59.5% vs. 35.7%; P = 0.029). No significant difference was observed in 28-day all-cause mortality (31.0% vs.…
How strong is the evidence?
Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 176 participants or records.
Read the paper
Related studies
- Severe clinical outcomes of COVID-19 associated with proton pump inhibitors: a nationwide cohort study with propensity score matching
- Penicillins for Treatment of Pneumococcal Pneumonia: Does In Vitro Resistance Really Matter?
- Thiophenes—Naturally Occurring Plant Metabolites: Biological Activities and In Silico Evaluation of Their Potential as Cathepsin D Inhibitors
- Inhalable Mannosylated Rifampicin–Curcumin Co-Loaded Nanomicelles with Enhanced In Vitro Antimicrobial Efficacy for an Optimized Pulmonary Tuberculosis Therapy
- Development and validation of microbial bioassay for quantification of Levofloxacin in pharmaceutical preparations
- Association between cord blood 25-hydroxyvitamin D concentrations and respiratory tract infections in the first 6 months of age in a Korean population: a birth cohort study (COCOA)
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.